{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:34:15Z","timestamp":1793799255927,"version":"4.6.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.esmoop.2026.108598","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:23:29Z","timestamp":1791505409000},"page":"108598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The cost of intensification in high-risk non\u2013muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2181-8405","authenticated-orcid":false,"given":"M.","family":"Zugman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kirche Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Baccaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2026.108598_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-471942","article-title":"New treatment options for non\u2013muscle-invasive bladder cancer","volume":"45","author":"Filon","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"16","key":"10.1016\/j.esmoop.2026.108598_bib3","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.esmoop.2026.108598_bib4","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108598_bib5","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"issue":"10516","key":"10.1016\/j.esmoop.2026.108598_bib6","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108598_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108598_bib8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41571-023-00823-5","article-title":"Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed","volume":"20","author":"Walia","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108598_bib9","doi-asserted-by":"crossref","first-page":"108529","DOI":"10.1016\/j.esmoop.2026.108529","article-title":"Safety profile of BCG with or without immunotherapy in non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis","volume":"11","author":"Ciccarese","year":"2026","journal-title":"ESMO Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:21:04Z","timestamp":1793798464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926025433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2059702926025433"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108598","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost of intensification in high-risk non\u2013muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108598"}}